Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27857377 | 0.87 | MET (0.41) | METCHRM1 | |
| SCHEMBL1190930 | 0.87 | MET (0.61) | METDPP4 | |
| SCHEMBL1161557 | 0.84 | MET (0.62) | MET | |
| SCHEMBL1161389 | 0.84 | MET (0.40) | MET | |
| SCHEMBL27857466 | 0.81 | MET (0.39) | METCHRM1 | |
| SCHEMBL1161273 | 0.81 | MET (0.39) | MET | |
| SCHEMBL1191437 | 0.80 | MET (0.42) | METCHRM1DPP4 | |
| SCHEMBL1161766 | 0.78 | MET (0.60) | MET | |
| SCHEMBL27857378 | 0.77 | MET (0.36) | METCHRM1 | |
| SCHEMBL14972736 | 0.77 | DPP4 (0.43) | METDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462143-B1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | NOVARTIS AG (CH) | 2013-05-29 | — | — | EP | claimed |
| US-8389526-B2 | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives | NOVARTIS AG (CH) | 2013-03-05 | — | — | US | claimed |
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | NOVARTIS AG (CH) | 2011-02-17 | — | — | US | claimed |
| EP-2462143-B1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | NOVARTIS AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8389526-B2 | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives | NOVARTIS AG (CH) | 2013-03-05 | — | — | US | disclosed |
| US-8389526-B2 | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives | NOVARTIS AG (CH) | 2013-03-05 | — | — | US | disclosed |
| US-8389526-B2 | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives | NOVARTIS AG (CH) | 2013-03-05 | — | — | US | disclosed |
| EP-2462143-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | NOVARTIS AG (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | NOVARTIS AG (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | NOVARTIS AG (CH) | 2011-02-17 | — | — | US | disclosed |
| WO-2011015652-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011015652-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | MET, ERBB2, ABL1 | MET 1/4885CHRM1 1655/4885DPP4 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.